Introduction of interest, these powerful new in vitro methods
The humoral immune system is incredibly diverse in its described above, when combined with the ability to ability to produce antibodies to virtually any target molexpress these antibody molecules inside the cell, provide ecule whether it be self or foreign, protein or nucleic acid, a rich source of human antibody genes and form the basis carbohydrate or lipid. Immunologic tolerance normally of an extraordinarily powerful new family of protein prevents the development of autoantibodies, however, molecules that have potential applications in the gene numerous disease states in humans provide evidence that therapy of a number of human diseases. [14] [15] [16] tolerance can be broken. Once these in vivo control mechanisms are removed, the development of human anti-
Intrabody design
bodies to virtually any molecule of interest, whether of human or microbial origin, should be readily achieved. By harvesting the power and diversity of the immune Indeed recently, a powerful new set of immunologic tools system in the form of rearranged antibody genes, the has been developed that has allowed human antibody immune system itself accomplishes the binding site genes to be easily manipulated. [1] [2] [3] Using these tools, the design, thereby bypassing some of the technical hurdles creation of large human immunoglobulin libraries from involved in RNA-based intracellular immunization stranaive individuals has been achieved and when combined tegies that use antisense, ribozymes and RNA decoys. A with phage display technology, has allowed investigators key factor contributing to the success of recent studies to bypass in vivo immunization and produce high-affinity has been the use of single-chain antibodies, also known human antibodies to human proteins. [4] [5] [6] [7] Smaller as single-chain variable region fragments or sFv, in which immunoglobulin libraries from individuals with autothe heavy-and light-chain variable domains are syntheimmune 8,9 or infectious diseases. 1,10,11 have allowed more sized as a single polypeptide and are separated by a flexdisease-specific antibodies to be readily isolated. Transible linker peptide, generally (Gly 4 -Ser) 3 . The constant genic mice that contain a human immunoglobulin locus portion of the immunoglobulin molecule, which has no in the absence of the corresponding mouse locus have role in antigen binding, is dispensed of entirely. The been produced and stable hybridomas that secrete result is a small (approximately 28 kDa) molecule with human antigen-specific antibodies have been high-affinity ligand-binding capability and minimal reported.
12,13 Thus, although almost all of the intrabodies assembly requirements. The addition of a human conthus far reported have used well characterized and affinstant domain to the carboxy-terminus of the sFv has ity matured rodent hybridoma cell lines as starting increased the activity of several of the anti-HIV-1 intrabodies discussed below. dase-H, consistent with its retention in a pre-Golgi compartment. The sFv intrabody was used to down-regulate our hands resulted in greater variability in the coexpression of the two chains. The intrabodies can be IL-2R␣ in several (IL-2-independent) HTLV-1-transformed cell lines which normally express high levels directed to the relevant cellular compartments by modifying the intrabody genes with N-terminus or C-ter-(approximately 200 000 molecules per cell) of IL-2R␣. IL-2R␣ expression was reduced to undetectable levels withminus polypeptide extensions that encode classical intracellular-trafficking signals.
14-16 Functional studies have out affecting cell viability or growth rate and therefore was not required for the growth of the cell lines that were illustrated that both sFv and Fab intrabodies are able to fold and assemble correctly in the cytoplasm, even examined. 26 Intrabodies against IL-2R␤ and ␥ c , which play a more direct role in IL-2 signal transduction, can be though: (1) the chaperones that would normally assist in this process are localized in the endoplasmic reticulum used in future studies to examine the role of IL-2 receptor signaling in the process of HTLV-1 leukemogenesis. (ER) and, therefore, unavailable; and (2) the reducing environment does not favor the formation of disulfide Although these intrabodies may offer significant potential for immunomodulation and for the control of bonds. However, it has been generally found that cytosolic intrabodies (whether they have intact chains, Fab or IL-2R-dependent tumor cell growth in vivo, especially when used in combination with targeted gene delivery sFv fragments) exhibit shorter half-lives than their secretory counterparts. 22 systems, further work will be required to validate these hypotheses.
Gene therapy applications of intrabodies
Targeted tumor killing via anti-erbB2 sFv
In principle, intrabodies can be used to modulate cellular tyrosine kinases which include erbB/EGFR, erbB2, erbB3 • modulate enzyme function by occluding an active site, and erbB4. ErbB2 becomes rapidly phosphorylated and sequestering substrate, or fixing the enzyme in an activated following ligand treatment of many cell lines. active (on) or inactive (off) conformation;
These naturally occurring ligands such as epidermal • divert proteins from their usual cellular compartment, growth factor (EGF) and Neu differentiation factor (NDF) for example, by sequestering transcription factors in do not bind directly to erbB2, and its activation is likely the cytoplasm, or by retention in the ER of proteins that to be mediated via transmodulation by other members of are destined for the cell surface or to be secreted.
the type I/EGF-related family of receptor tyrosine kinases (RTKs). 27 ErbB2 is amplified or overexpressed in a variety of human tumors, including breast and ovarian Down-regulation of growth-factor receptors carcinoma, where it correlates with an unfavorable prognosis. [28] [29] [30] [31] Intrabodies that are targeted to the lumen of the ER provide a simple and effective mechanism for inhibiting the Two KDEL-tagged sFv intrabodies have been shown to decrease markedly the cell-surface expression of erbB2 transport of plasma membrane or secreted proteins to the cell surface; even highly abundant cell-surface receptors in NIH3T3 fibroblasts that express an oncogenically activated form of erbB2. Functional inactivation of the recephave been reduced to undetectable levels using this method. Intrabodies that are intended for localization in tor was suggested by a reduction in the phosphotyrosine content of the cells and, more importantly, by the reverthe ER are generally equipped with a leader peptide and a C-terminus ER retention signal (the KDEL amino acid sion of the cells to a non-transformed phenotype. 32 One of these KDEL-tagged sFv intrabodies was further studmotif -Lys-Asp-Glu-Leu). In practice, the KDEL tag is not always necessary since a number of sFv intrabodies ied in T47D human mammary carcinoma cells that express four members of the type I/epidermal growth designed for secretion appear to be export incompetent and remain in the ER for reasons that are, at present, factor receptor family including erbB/EGFR, erbB2, erbB3 and erbB4. Analysis of signals elicited by ligands of unclear.
23-25
A KDEL-tagged sFv intrabody has been used to down-EGFR, erbB3 and erbB4 demonstrated that in cells stably expressing the anti-erbB2 KDEL-tagged sFv intrabody regulate the ␣ subunit of the receptor for human interleukin 2 (IL-2R␣, Tac, CD25).
25 IL-2R␣ plays a key role in and selectively lacking cell surface erbB2, phosphorylation of Shc, activation of MAPK and p70/p85 S6K , and T cell-mediated immune responses, and is constitutively overexpressed in some T and B cell leukemias, most induction of c-fos expression in response to both EGF and NDF were impaired. 27 These studies also show the notably in adult T cell leukemia (ATL) which is caused by HTLV-1. The specific induction of IL-2R␣ on all HTLV-1-importance of receptor transmodulation among the type I RTKs. transformed cells, including fresh ATL cells, has led to the hypothesis that IL-2 receptor signaling may be In complementary studies, an ER-directed sFv intrabody has been used to down-regulate erbB2 in the human involved in the process of HTLV-1 leukemogenesis. An ER-targeted sFv derivative of the anti-Tac monoclonal ovarian-carcinoma cell line SKOV3. Transient expression 
Inhibition of virus replication
erbB2 expression at the cell surface. Furthermore, it was difficult to establish SKOV3 clones that stably expressed Intrabodies have important therapeutic potential in the the anti-erbB2 sFv intrabody, suggesting that constitutive defense of microbial pathogens. One study has demondown-regulation of erbB2 is incompatible with the longstrated inhibition of infectious tick-borne flavivirus proterm survival of these cells. 33 When ex vivo-transduced duction by cytosolic sFv intrabodies directed against a SKOV3 cells were introduced subcutaneously into nude cross-reactive epitope on the envelope protein of louping mice, no tumor grew and complete tumor eradication at ill and some other tick-borne encephalitis viruses. 43 In necropsy 80 days after s.c. transplant occurred only in another study, inhibition of HTLV-1 Tax-mediated transmice receiving the anti-erbB2 expressing cells in marked activation of the HTLV-1 LTR was demonstrated. 44 Howcontrast to mice receiving the control transduced cells. 34 ever, perhaps no better example of the broad use of intraTumor cell eradication in transduced primary cultures of bodies for the gene therapy of a human infectious disease human ovarian carcinoma cells could also be demoncomes from studies on the human immunodeficiency strated. 34 Using a replication-defective adenovirus to in virus, HIV-1. Indeed, sFv and Fab intrabodies have been vivo transduce the anti-erbB2 sFv intrabody gene into i.p.
used to prevent HIV-1 replication by blocking both posttransplanted SKOV3 cells, these investigators further integration and pre-integration steps in the virus life demonstrated in vivo tumor cell killing and a significantly cycle. Post-integration inhibition of HIV-1 replication has prolonged survival of animals compared with control been achieved by blocking of gp120 processing and incorgroups. 35 Although issues related to in vivo gene delivery poration into virions. 19,21,25,45, 46 Transduction of a human and nonspecific toxicity still exist, 36 based on these and anti-gp120 sFv intrabody gene into PBMCs from both other preclinical data, a clinical gene therapy protocol to uninfected and HIV-1-infected patients has been reported treat metastatic ovarian cell carcinoma in patients that using murine leukemia virus (MuLV) vectors that encohave failed conventional chemotherapy was approved by ded the sFv intrabody gene under the control of an the United States Recombinant DNA Advisory Commitinternal CMV promoter. 45, 46 In HIV-1 challenge experitee (RAC) in 1995.
ments, both cytoprotection and inhibition of HIV-1 replication were observed. Based on these encouraging results, a clinical gene therapy protocol was approved by
Inactivation of cytosolic oncoproteins
the RAC in 1995. This study will evaluate the safety and Several groups of investigators have constructed intraefficacy of intracellular antibody gene therapy in bodies, derived from the parental hybridoma Y13-259, to asymptomatic patients with HIV-1 infection by reinfusperturb the function of p21 ras , a guanine nucleotide-binding autologous CD4 + T cells that have been transduced ing protein that is strategically involved in the control of ex vivo with a MuLV vector that expresses the anti-gp120 cell growth and differentiation. [37] [38] [39] [40] [41] Members of the ras sFv intrabody. In addition to following various immunogene family have been implicated in many types of logic and viral parameters, the in vivo kinetics and surhuman cancer. Intrabody expression in the cytosol has vival of intrabody-transduced cells will be compared by generally been accomplished by simple removal of the limiting dilution PCR with those of a separate aliquot of immunoglobulin leader sequences. In two studies, cells transduced with a control vector (identical except microinjection of mRNA encoding an anti-p21 ras sFv for the intrabody gene). intrabody was microinjected into Xenopus oocytes and Post-integration blockage of HIV-1 replication by was shown to inhibit insulin-induced meiotic maturation inhibiting critical HIV-1 regulatory protein functions of the cell, a process known to be p21 ras -dependent. 37, 38 such as Tat-mediated viral transcriptional transactivMeiotic maturation was not inhibited in oocytes that coation, 45, 47 or Rev-mediated nuclear export of singly expressed cytosolic forms of the separate heavy and light spliced or genomic viral RNA 48-50 has also been reported. chains, presumably reflecting the more stringent Potent antiviral activity against a panel of primary HIV-1 assembly requirements of a native four-chain antibody.
isolates has been demonstrated. Intrabodies against these In other studies in Xenopus oocytes, activation of p42 viral proteins are particularly attractive for clinical gene mitogen-activated protein kinase (MAPK) by ras was also therapy trials because of the essential role of these prostrongly inhibited by the sFv intrabody. 40 Two groups teins in the viral life cycle. have transfected either sFv intrabodies 40 or whole Pre-integration blockade of virus replication has been immunoglobulin heavy and light chains (in separate demonstrated with Fab intrabodies against the HIV-1 expression plasmids) 41 into morphologically transformed matrix protein (MA, p17) 21 and reverse transcriptase. when used in combination in bicistronic gene transfer Cyclin D1 overexpression contributes to the transforvectors, 20,21 provides an approach that may prove more med phenotype of numerous cancerous cell lines. Predurable in suppressing virus replication than single intraliminary data have been presented on the inhibitory body therapy alone. Indeed, the recent success of pharmeffect of an anti-human D1 sFv intrabody in stably transacologic-based studies that have compared combination fected MCF7 breast cancer cell lines. 42 Intrabodies that agent therapy with single agent therapy lends support to interfere with the function of cytosolic kinases, GTPases this idea. [51] [52] [53] Intrabodies against cellular proteins that or other molecules involved in signal transduction could may prevent or negatively modulate HIV-1 replication prove extremely valuable in unravelling the complex and will be an important area of research in the future. Candiinterconnecting pathways that serve to deliver extracellular signals to the nucleus.
date cellular proteins include the HIV-1 co-receptors can be widely applied in the clinical context. These it is difficult to predict the success or failure of the clinical 22 
